Kyverna Therapeutics (Kyverna Therapeutics) Other Gross PPE : $14.43 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Other Gross PPE?

Kyverna Therapeutics's Other Gross PPE for the quarter that ended in Mar. 2024 was $14.43 Mil.

Kyverna Therapeutics's quarterly Other Gross PPE declined from Sep. 2023 ($12.59 Mil) to Dec. 2023 ($12.34 Mil) but then increased from Dec. 2023 ($12.34 Mil) to Mar. 2024 ($14.43 Mil).

Kyverna Therapeutics's annual Other Gross PPE increased from Dec. 2021 ($8.23 Mil) to Dec. 2022 ($13.39 Mil) but then declined from Dec. 2022 ($13.39 Mil) to Dec. 2023 ($12.34 Mil).

Kyverna Therapeutics Other Gross PPE Historical Data

The historical data trend for Kyverna Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Other Gross PPE Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Other Gross PPE

8.23

13.39

12.34

Kyverna Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Other Gross PPE	Get a 7-Day Free Trial			13.39	-	12.59	12.34	14.43

Kyverna Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, STE 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines

From GuruFocus

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

By PRNewswire • 02-12-2024